A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients

PHASE3

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped The study was stopped due to insurmountable enrollment challenges affecting trial accrual, resulting from the rapidly evolving treatment options for advanced prostate cancer.

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG: Enzalutamide during Lead-in Period
DRUG: Lead-in Enzalutamide followed by Radium-223/Enzalutamide
DRUG: Lead-in Enzalutamide followed by Placebo/Enzalutamide
DRUG: Darolutamide during Lead-in Period
DRUG: Lead-in Darolutamide followed by Radium-223/Darolutamide
DRUG: Lead-in Darolutamide followed by Placebo/Darolutamide

Sponsor

MANA RBM

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]